Lukas Peeters, Mick Hoen, Delian Hofman, Bjorn Hompes, Bart Langenveld, Danae Smeets, Timo Lenderink, Hans Peter Brunner-La Rocca, Sandra Sanders-van Wijk
{"title":"PRACTICE-HF: Implementation of an updated clinical protocol for acute heart failure.","authors":"Lukas Peeters, Mick Hoen, Delian Hofman, Bjorn Hompes, Bart Langenveld, Danae Smeets, Timo Lenderink, Hans Peter Brunner-La Rocca, Sandra Sanders-van Wijk","doi":"10.1007/s12471-025-02004-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Despite recent advances in the treatment of acute heart failure (AHF), implementation of new evidence into clinical practice remains challenging.</p><p><strong>Methods: </strong>We conducted a single-center descriptive exploratory study within an ongoing prospective AHF registry. Adult patients admitted with AHF, without requiring intensive care, were included consecutively. An updated local AHF protocol was developed and implemented by group-education sessions, pocket cards, and posters. Patients before (control group) and after (intervention group) implementation of the new protocol were compared in terms of compliance to the protocol and 90-day outcomes-blanking the implementation period. Subgroups entailed HF with (mildly) reduced and preserved ejection fraction.</p><p><strong>Results: </strong>Patients were elderly, with almost half being de novo HF patients. Groups were comparable except for higher NT-proBNP in the implementation group and a higher cancer prevalence in the control group. The intervention group showed an increase in in-hospital use of acetazolamide (59.8 vs 0%, p < 0.001), in iron deficiency testing and correct iv. iron administration (42.9% vs 78.6% p ≤ 0.001). Pre-discharge installation of SGLT2 inhibitors showed a positive trend (44.2 vs 20% in HF(m)rEF patients and 29.4 vs 4% in HFpEF, both p = 0.01) HF-event-free survival at 90 days numerically favored the intervention group (29.9 vs 44.3%, p = 0.054), whereas length of hospital stay increased by 1 day (p = 0.011).</p><p><strong>Conclusion: </strong>Implementing a local updated AHF protocol improved adoption of several evidence based AHF interventions. This may translate into improved patient outcomes, against a minor increase in hospital duration.</p>","PeriodicalId":18952,"journal":{"name":"Netherlands Heart Journal","volume":" ","pages":"46-53"},"PeriodicalIF":2.5000,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12852520/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Netherlands Heart Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12471-025-02004-8","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/5 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Despite recent advances in the treatment of acute heart failure (AHF), implementation of new evidence into clinical practice remains challenging.
Methods: We conducted a single-center descriptive exploratory study within an ongoing prospective AHF registry. Adult patients admitted with AHF, without requiring intensive care, were included consecutively. An updated local AHF protocol was developed and implemented by group-education sessions, pocket cards, and posters. Patients before (control group) and after (intervention group) implementation of the new protocol were compared in terms of compliance to the protocol and 90-day outcomes-blanking the implementation period. Subgroups entailed HF with (mildly) reduced and preserved ejection fraction.
Results: Patients were elderly, with almost half being de novo HF patients. Groups were comparable except for higher NT-proBNP in the implementation group and a higher cancer prevalence in the control group. The intervention group showed an increase in in-hospital use of acetazolamide (59.8 vs 0%, p < 0.001), in iron deficiency testing and correct iv. iron administration (42.9% vs 78.6% p ≤ 0.001). Pre-discharge installation of SGLT2 inhibitors showed a positive trend (44.2 vs 20% in HF(m)rEF patients and 29.4 vs 4% in HFpEF, both p = 0.01) HF-event-free survival at 90 days numerically favored the intervention group (29.9 vs 44.3%, p = 0.054), whereas length of hospital stay increased by 1 day (p = 0.011).
Conclusion: Implementing a local updated AHF protocol improved adoption of several evidence based AHF interventions. This may translate into improved patient outcomes, against a minor increase in hospital duration.
背景:尽管急性心力衰竭(AHF)的治疗最近取得了进展,但将新证据应用于临床实践仍然具有挑战性。方法:我们在正在进行的前瞻性AHF登记中进行了一项单中心描述性探索性研究。连续纳入不需要重症监护的AHF成年患者。通过小组教育会议、口袋卡片和海报,开发和实施了更新的当地AHF协议。比较新方案实施前(对照组)和实施后(干预组)患者对新方案的依从性和90天结果(空白实施期)。亚组为HF伴(轻度)射血分数降低和保留。结果:患者为老年人,近一半为新发HF患者。除了实施组NT-proBNP较高和对照组癌症患病率较高外,各组具有可比性。干预组显示院内乙酰唑胺使用量增加(59.8% vs 0%, p )。结论:实施当地更新的AHF方案改善了几种基于证据的AHF干预措施的采用。这可能转化为改善患者的结果,而住院时间略有增加。
期刊介绍:
The scope of the Netherlands Heart Journal is to contribute to the national and international literature by publishing scientific papers in the field of cardiovascular medicine. It also provides a platform for Continuing Medical Education for cardiologists and those in training for the speciality of cardiology in the Netherlands.
The Netherlands Heart Journal is made available to cardiologists, cardiologists in training, cardiopulmonary surgeons, cardiopulmonary surgeons in training, internists and paediatric cardiologists. The journal is the official journal of the Netherlands Society of Cardiology.